Joel P Berger

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. Berger J, Moller D. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35 pubmed
    ..Here, we present the current state of knowledge regarding the molecular mechanisms of PPAR action and the involvement of the PPARs in the etiology and treatment of several chronic diseases. ..
  2. Berger J, Patel H, Woods J, Hayes N, Parent S, Clemas J, et al. A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol. 2000;162:57-67 pubmed
    ..Thus, nuclear localization of PPARgamma occurs independently of its activation state. The dominant negative mutant, hPPARgamma2Delta500, may prove useful in further studies to characterize PPAR functions both in vitro and in vivo ..

Detail Information

Publications2

  1. Berger J, Moller D. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35 pubmed
    ..Here, we present the current state of knowledge regarding the molecular mechanisms of PPAR action and the involvement of the PPARs in the etiology and treatment of several chronic diseases. ..
  2. Berger J, Patel H, Woods J, Hayes N, Parent S, Clemas J, et al. A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol. 2000;162:57-67 pubmed
    ..Thus, nuclear localization of PPARgamma occurs independently of its activation state. The dominant negative mutant, hPPARgamma2Delta500, may prove useful in further studies to characterize PPAR functions both in vitro and in vivo ..